An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
RenovoRx to Host “Delivering Therapy Where it Matters” Fireside Chat with CEO, Shaun Bagai, on February 23rd at 12 P.M. ET
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
RenovoRx, Inc. (Nasdaq: RNXT) will host a fireside chat titled “Delivering Therapy Where it Matters” on February 23 at 12 p.m. ET, featuring CEO Shaun Bagai. The session will focus on the company's localized chemotherapy approach and its 2022 milestones. Participants can engage in a Q&A. RenovoRx is known for its RenovoTAMP therapy platform, targeting difficult tumors. Its lead candidate, RenovoGem, is being tested in the Phase 3 TIGeR-PaC trial for locally advanced pancreatic cancer.
Positive
None.
Negative
None.
LOS ALTOS, Calif.--(BUSINESS WIRE)--
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, will host the “Delivering Therapy Where it Matters” fireside chat with CEO, Shaun Bagai, on Wednesday, February 23rd at 12 p.m. ET.
During the video webinar, Mr. Bagai will discuss RenovoRx’s unique approach to fighting cancer through localized and targeted chemotherapy. Additionally, he will review the Company’s anticipated milestones for 2022 and discuss the Company’s plan to execute on its vision to develop innovative therapies that decrease side effects typical of systemic chemotherapy, while improving quality of life for cancer patients. The webinar is open to the public. Participants will have an opportunity to ask questions during the Q & A portion of the webinar.
For additional information please contact KCSA Strategic Communications by emailing RenovoRx@KCSA.com.
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and our patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.
RenovoRx’s patent portfolio includes seven U.S. patents for its technology. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.
RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.
